Cited by 133Tissue Engineering and Regenerative MedicinePancreatic function and diabetes3D Printing in Biomedical Research

The Human Pancreas as a Source of Protolerogenic Extracellular Matrix Scaffold for a New-generation Bioartificial Endocrine Pancreas

Open access
Peloso, Andrea, Urbani, Luca, Cravedi, Paolo, Katari, Ravi, Maghsoudlou, Panagiotis, Fallas, Mario Enrique Alvarez, Sordi, Valeria, Citro, Antonio +15 more·2016·Annals of Surgery

Abstract

OBJECTIVES: Our study aims at producing acellular extracellular matrix scaffolds from the human pancreas (hpaECMs) as a first critical step toward the production of a new-generation, fully human-derived bioartificial endocrine pancreas. In this bioartificial endocrine pancreas, the hardware will be represented by hpaECMs, whereas the software will consist in the cellular compartment generated from patient's own cells. BACKGROUND: Extracellular matrix (ECM)-based scaffolds obtained through the decellularization of native organs have become the favored platform in the field of complex organ bioengineering. However, the paradigm is now switching from the porcine to the human model. METHODS: To achieve our goal, human pancreata were decellularized with Triton-based solution and thoroughly characterized. Primary endpoints were complete cell and DNA clearance, preservation of ECM components, growth factors and stiffness, ability to induce angiogenesis, conservation of the framework of the innate vasculature, and immunogenicity. Secondary endpoint was hpaECMs' ability to sustain growth and function of human islet and human primary pancreatic endothelial cells. RESULTS: Results show that hpaECMs can be successfully and consistently produced from human pancreata and maintain their innate molecular and spatial framework and stiffness, and vital growth factors. Importantly, hpaECMs inhibit human naïve CD4 T-cell expansion in response to polyclonal stimuli by inducing their apoptosis and promoting their conversion into regulatory T cells. hpaECMs are cytocompatible and supportive of representative pancreatic cell types. DISCUSSION: We, therefore, conclude that hpaECMs has the potential to become an ideal platform for investigations aiming at the manufacturing of a regenerative medicine-inspired bioartificial endocrine pancreas.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/sla.0000000000001364

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • dECM-based scaffolds are more biocompatible and confront less rejection rate compared to other implants.

    “Thereby, dECM-based scaffolds are more biocompatible and confront less rejection rate compared to other implants [30–32].”

    From Immunogenicity of decellularized extracellular matrix scaffolds: a bottleneck in tissue engineering and regenerative medicine (2023) · cites this paper as [31]

    The Discussion (page unavailable) reports that human pancreatic dECM scaffolds supported islet and endothelial-cell attachment and function, and showed immunosuppressive, Treg-promoting properties. These findings support cytocompatibility and a possible immune benefit, but the paper does not compare the scaffolds with other implants or report lower rejection rates. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • dECM scaffolds affect CD4+ T cell maturation and differentiation to shift T cell polarization toward regulatory phenotype (T reg), an immunomodulatory subtype that downregulates T cell activity.

    “dECM scaffolds affect CD4+ T cell maturation and differentiation to shift T cell polarization toward regulatory phenotype (T reg), an immunomodulatory subtype that downregulates T cell activity.”

    From Immunogenicity of decellularized extracellular matrix scaffolds: a bottleneck in tissue engineering and regenerative medicine (2023) · cites this paper as [31]

    Results §3.8 reports that human pancreatic decellularized ECM scaffolds inhibit naïve CD4+ T-cell proliferation and promote conversion to regulatory T cells, which the section describes as inhibiting effector T-cell activity. The claim generalizes this finding to dECM scaffolds broadly, whereas the paper tested pancreatic scaffolds specifically. Page numbers were not available in our copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 1

  1. [16]Salvatori M Peloso A Katari R Semi-xenotransplantation: combining transplantation with organ bioengineering and regeneration technologies to manufacture complex modular organs Xenotransplantation 2015 22 1 6 Mirmalek-Sani A Orlando G McQuilling J Porcine pancreas extracellular matrix as a platform for endocrine pancreas bioengineering Biomaterials 2013 34 5488 5495 23583038 PMC3680884

Cited by

Sorted by citations

Authors
Peloso, A., Urbani, L., Cravedi, P., Katari, R., Maghsoudlou, P., Fallas, M. E. A., Sordi, V., Citro, A., Purroy, C., Niu, G., McQuilling, J. P., Sittadjody, S., Farney, A. C., Iskandar, S. S., Zambon, J. P., Rogers, J., Stratta, R. J., Opara, E. C., Piemonti, L., Furdui, C. M., Soker, S., De Coppi, P., & Orlando, G.
Affiliations
Great Ormond Street Hospital (GB)
Venue
Annals of Surgery
Published
2016-07
Volume
264
Issue
1
Pages
169-179
ISSN
0003-4932 (ISSN-L)
OpenAlex
W2325796265
Cited by
133
References
30
Citations by year
2025: 7 · 2024: 7 · 2023: 13 · 2022: 10 · 2021: 14 · 2020: 21 · 2019: 18 · 2018: 19 · 2017: 14 · 2016: 8 · 2015: 1
FWCI
14.11
Type
journal article
Language
en
Open access
Locations
  • Annals of Surgery (publishedVersion)
  • PubMed (publishedVersion)
  • Explore Bristol Research (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, cc-by-nc-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • Bristol Research (University of Bristol) (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
  • National Institute for Health and Care Research (RP_2014-04-046)
  • National Institute of Allergy and Infectious Diseases (T32AI078892)
  • National Institute of Biomedical Imaging and Bioengineering (T32EB014836)
Topics
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
Keywords
human pancreas, extracellular matrix scaffolds, decellularization, islet transplantation, regulatory T cells, CD4+ T cell apoptosis, immunogenicity, angiogenesis, tissue stiffness, growth factors, regenerative medicine
MeSH terms
Extracellular Matrix, Humans, Islets of Langerhans, Pancreas, Regeneration, Tissue Engineering, Organogenesis, Tissue Scaffolds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review